Mechanical ventilation (MV) although life-saving, can also be harmful:

  • MV and sedation cause the disused diaphragm muscle to atrophy rapidly and profoundly (ventilator induced diaphragm dysfunction; VIDD*)
  • Positive-pressure ventilation often damages the lungs (ventilator induced lung injury; VILI) and may lead to ventilatorassociated pneumonia (VAP)
  • MV requires intubation and depending on the injury or illness may require a tracheostomy whenever mechanical ventilation has to continue for a longer period of time
  • Ventilated patients are at high risk of contracting nosocomial (hospital-acquired) bacterial and fungal infections

* Levine S, Nguyen T, et al. “Rapid Disuse Atrophy of Diaphragm Fibers in Mechanically Ventilated Humans” N Engl J Med 358: 1327-35, 2008.

VIDD, VILI and VAP are key contributing factors to the frequent difficulty in weaning patients from the ventilator. About 31% of patients on MV are categorized as ‘difficult to wean’ when they fail one or more spontaneous breathing trials or need to be re-intubated within 48 hours of extubation.

About 35% of ventilated patients require prolonged weaning periods of over 96 hours, and over 20% are still on MV at 7 days. These are the most expensive patients in the hospital. The U.S. cost of prolonged MV patients in 2020 is projected to exceed $60 Billion**. When a patient becomes ventilator-dependent, their risk of dying in the ICU increases 7-fold.

** Zilberberg, Prolonged acute mechanical ventilation and hospital bed utilization in 2020 in the United States: implications for budgets, plant and personnel planning. BMC Health Services Research, 2008, 8:242.

Intravenously inserted LIVE Catheter is designed to rhythmically activate the diaphragm. In the patients who have failed or would typically fail to wean and become ventilator-dependent, the pacing therapy is expected to prevent or reverse diaphragm muscle-disuse atrophy and maintain diaphragmatic endurance, thus facilitating weaning of patients from MV. In addition, the paced diaphragm is expected to restore negative pressure ventilation, thereby potentially providing a more physiological respiratory pattern and reducing the levels of positive pressure ventilation and its harmful effects on the lungs.

The potentially beneficial effects of Lungpacer Diaphragm Pacing Therapy (DPT) are expected to result in faster patient recovery, a shorter stay in the intensive care unit, improved health outcomes and lower healthcare costs.

Get in touch

Corporate Headquarters

Lungpacer Medical Inc.
8602 Commerce Court
Burnaby, B.C. V5A 4N6
Canada

USA

Lungpacer Medical USA Inc.
260 Sierra Drive, #116
Exton, PA 19341
USA

Caution: Investigational Device
The Lungpacer Diaphragm Pacing Therapy System is limited by Federal (United States) law to investigational use.The device is not approved for sale in the United States or Europe.Lungpacer®, Weaning Solution®, Lungpacer DPT System™, Lungpacer DPT™, LIVE Catheter® are registered trademarks of Lungpacer Medical.